Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | HTR6 | P50406 | 11/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30411274 | 1.00 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL22516604 | 0.85 | PKM (0.62) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL23620190 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL2011040 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL2009025 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL18370167 | 0.81 | CYP2C19 (0.61) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL1963075 | 0.81 | CYP2C19 (0.57) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL23971058 | 0.79 | CYP2C19 (0.58) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL20355041 | 0.78 | CYP2C19 (0.57) | CYP2C19HTR6MEN1KMT2AHTT | |
| SCHEMBL23970944 | 0.78 | CYP2C19 (0.57) | CYP2C19HTR6MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115551862-B | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-116283712-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-116036078-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115551862-A | Macrocyclic inhibitors of peptidyl arginine deiminase | 吉利德科学公司 | 2022-12-30 | — | — | CN | disclosed |
| CN-110121499-B | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2022-12-20 | — | — | CN | disclosed |
| WO-2022140390-A1 | INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| US-8252930-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2012-08-28 | — | — | US | disclosed |
| EP-2041131-B1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-09-28 | — | — | EP | disclosed |
| US-7964728-B2 | Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. (NL) | 2011-06-21 | — | — | US | disclosed |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. | 2011-03-03 | — | — | US | disclosed |
| CN-101484454-A | Azaindole derivatives with a combination of partial nicotinic acetylcholine receptor agonism and dopamine reuptake inhibition | SOLVAY PHARM B V (NL) | 2009-07-15 | — | — | CN | disclosed |
| EP-2041131-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | Solvay Pharmaceuticals B.V. (NL) | 2009-04-01 | — | — | EP | disclosed |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | ABBVIE B.V. (NL) | 2008-01-10 | — | — | US | disclosed |
| WO-2008003736-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYLCHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | CYP2C19 1298/4885HTR6 638/4885MEN1 2601/4885 |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | CYP2C19 1298/4885HTR6 638/4885MEN1 2601/4885 |
| US-20080009514-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | CYP2C19 662/4885HTR6 70/4885MEN1 3501/4885 |
| US-20110053962-A1 | AZAINDOLE DERIVATIVES WITH A COMBINATION OF PARTIAL NICOTINIC ACETYL-CHOLINE RECEPTOR AGONISM AND DOPAMINE REUPTAKE INHIBITION | CHRNA5, CHRNA7, CHRNA2 | CYP2C19 586/4885HTR6 74/4885MEN1 3344/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | CYP2C19 4214/4885HTR6 1495/4885MEN1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.